HIMS’ $300M Offering Gets Thumbs Up From Investors – Retail Shrugs Off Slide In Stock Price

• The company said the proceeds will help maintain financial flexibility in international expansion efforts, including its proposed acquisition of Eucalyptus.
• HIMS had earlier signed a $1.15 billion acquisition agreement with the Australian telehealth services firm, which is expected to close by mid-2026.
• Part of the proceeds will fund capped call transactions to reduce potential dilution, HIMS said.

Hims & Hers Health, Inc. (HIMS) on Monday unveiled plans to raise $300 million through a private offering of convertible senior notes due 2032 to fund its global expansion plans.

Following the announcement, the stock slid more than 5% in pre-market trading, with the HIMS ticker among the top-trending tickers on the platform at the time of writing.

Funds To Boost HIMS Expansion, AI Investment

Apart from the $300 million offering, Hims & Hers Health also plans to give initial buyers the option to purchase up to an additional $45 million in notes within 13 days of the initial issuance.

The company said the proceeds will help maintain financial flexibility as it pursues international expansion efforts, including its proposed acquisition of Eucalyptus, which is expected to close in mid-2026. The company also plans to invest in technology, fulfillment infrastructure, and artificial intelligence capabilities, it said.

Part of the proceeds will fund capped call transactions designed to reduce potential dilution of the company’s common stock if the notes are converted.

Earlier this year, Hims & Hers Health signed a definitive agreement to acquire Australian telehealth firm Eucalyptus for up to $1.15 billion. The acquisition is expected to open up markets in Australia and Japan, the company had said.

Retail Buoyant On HIMS Offering

Retail sentiment on Stocktwits turned ‘bearish’ from ‘neutral’ a day earlier, while message volumes remained ‘extremely high.’

One user described the sell-off as a case of investors “panicking.”

Another user said the offering will eventually accelerate the company’s plans.

Wall Street Is Bullish On HIMS’ Transition

Last week, the telehealth company reported weaker-than-expected first-quarter results, but Wall Street remained optimistic about its long-term growth prospects.

The company reported first-quarter revenue of $608.1 million, up 4% but below Wall Street expectations of $616.85 million, according to Fiscal.ai data. HIMS also posted a loss of $0.40 per share, compared to analysts’ estimates for earnings of $0.03 per share.

However, Citi, Needham, and Canaccord Genuity all raised their price targets on the stock after the results, highlighting the potential of the Novo Nordisk partnership and the transition to branded GLP-1 weight-loss drugs.

Read also: CMPS Stock Is Breaking Out Again — Retail Traders Think A Major FDA Catalyst Is Brewing

For updates and corrections, email newsroom[at]stocktwits[dot]com.